About Neurocrine Biosciences (NASDAQ:NBIX)

Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease. It is also developing NBI-74788, which is in Phase II clinical trial that is used for the treatment of congenital adrenal hyperplasia. In addition, the company's research programs comprise VMAT2 Inhibitors for movement disorders, bipolar disorders, and schizophrenia; and G Protein-Coupled Receptors and Ion Channels for epilepsy, essential tremor, pain, dystonia, and other indications. It has collaborations and agreements with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL ? Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson's disease. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:NBIX
CUSIP64125C10
Phone858-617-7600
Debt
Debt-to-Equity Ratio0.99%
Current Ratio10.20%
Quick Ratio10.20%
Price-To-Earnings
Trailing P/E Ratio-49.01
Forward P/E Ratio-349.74
P/E GrowthN/A
Sales & Book Value
Annual Sales$161.63 million
Price / Sales44.73
Cash FlowN/A
Price / CashN/A
Book Value$4.21 per share
Price / Book19.11
Profitability
EPS (Most Recent Fiscal Year)($1.62)
Net Income$-142,540,000.00
Net MarginsN/A
Return on Equity-43.46%
Return on Assets-21.65%
Miscellaneous
Employees400
Outstanding Shares89,880,000
Neurocrine Biosciences (NASDAQ:NBIX) Frequently Asked Questions
What is Neurocrine Biosciences' stock symbol?
Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."
How were Neurocrine Biosciences' earnings last quarter?
Neurocrine Biosciences (NASDAQ:NBIX) released its quarterly earnings results on Tuesday, February, 13th. The company reported $0.07 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.18 by $0.11. The company earned $94.52 million during the quarter, compared to the consensus estimate of $94 million. During the same quarter in the previous year, the company earned ($0.51) EPS. View Neurocrine Biosciences' Earnings History.
When is Neurocrine Biosciences' next earnings date?
What price target have analysts set for NBIX?
13 Wall Street analysts have issued 1 year target prices for Neurocrine Biosciences' stock. Their forecasts range from $65.00 to $113.00. On average, they anticipate Neurocrine Biosciences' stock price to reach $95.2308 in the next twelve months. View Analyst Ratings for Neurocrine Biosciences.
Who are some of Neurocrine Biosciences' key competitors?
Some companies that are related to Neurocrine Biosciences include Novozymes (NVZMY), bluebird bio (BLUE), Seattle Genetics (SGEN), AveXis (AVXS), Bio-Techne (TECH), Spark Therapeutics (ONCE), arGEN-X BV (ARGX), China Biologic Products (CBPO), Halozyme Therapeutics (HALO), CRISPR Therapeutics (CRSP), Aerie Pharmaceuticals (AERI), Denali Therapeutics (DNLI), Sangamo Therapeutics (SGMO), Repligen (RGEN), Acceleron Pharma (XLRN), Editas Medicine (EDIT), Momenta Pharmaceuticals (MNTA) and Atara Biotherapeutics (ATRA).
Who are Neurocrine Biosciences' key executives?
Neurocrine Biosciences' management team includes the folowing people:
- Dr. Kevin C. Gorman, CEO & Director (Age 60)
- Dr. Haig P. Bozigian Ph.D., Chief Devel. Officer (Age 60)
- Mr. Eric S. Benevich, Chief Commercial Officer (Age 53)
- Dr. Christopher F. O'Brien, Exclusive Consultant (Age 61)
- Mr. Matthew C. Abernethy, CFO & Principal Accounting Officer
Has Neurocrine Biosciences been receiving favorable news coverage?
News stories about NBIX stock have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies negative and positive news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Neurocrine Biosciences earned a daily sentiment score of 0.03 on Accern's scale. They also assigned media coverage about the company an impact score of 45.50 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.
How do I buy shares of Neurocrine Biosciences?
Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Neurocrine Biosciences' stock price today?
One share of NBIX stock can currently be purchased for approximately $80.26.
How big of a company is Neurocrine Biosciences?
Neurocrine Biosciences has a market capitalization of $7.14 billion and generates $161.63 million in revenue each year. The company earns $-142,540,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis. Neurocrine Biosciences employs 400 workers across the globe.
How can I contact Neurocrine Biosciences?
Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at 858-617-7600 or via email at [email protected]
MarketBeat Community Rating for Neurocrine Biosciences (NBIX)
MarketBeat's community ratings are surveys of what our community members think about Neurocrine Biosciences and other stocks. Vote "Outperform" if you believe NBIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NBIX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Neurocrine Biosciences (NASDAQ:NBIX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
13 Wall Street analysts have issued ratings and price targets for Neurocrine Biosciences in the last 12 months. Their average twelve-month price target is $95.2308, suggesting that the stock has a possible upside of 18.39%. The high price target for NBIX is $113.00 and the low price target for NBIX is $65.00. There are currently 13 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
Consensus Rating: | Buy | Buy | Buy | Buy |
Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 2.94 |
Ratings Breakdown: | 0 Sell Rating(s) 0 Hold Rating(s) 13 Buy Rating(s) 0 Strong Buy Rating(s) | 0 Sell Rating(s) 0 Hold Rating(s) 13 Buy Rating(s) 0 Strong Buy Rating(s) | 0 Sell Rating(s) 0 Hold Rating(s) 17 Buy Rating(s) 0 Strong Buy Rating(s) | 0 Sell Rating(s) 1 Hold Rating(s) 16 Buy Rating(s) 0 Strong Buy Rating(s) |
Consensus Price Target: | $95.2308 | $95.2308 | $82.3125 | $69.3125 |
Price Target Upside: | 18.39% upside | 12.26% upside | 1.16% upside | 17.56% upside |
Neurocrine Biosciences (NASDAQ:NBIX) Consensus Price Target History

Neurocrine Biosciences (NASDAQ:NBIX) Analyst Ratings History
Show:
(Data available from 4/23/2016 forward)
Neurocrine Biosciences (NASDAQ:NBIX) Dividend History by Quarter
Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
---|
(Data available from 1/1/2013 forward)
Neurocrine Biosciences (NASDAQ NBIX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 4.30%
Neurocrine Biosciences (NASDAQ NBIX) Insider Trading History
Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
---|
3/5/2018 | Haig P Bozigian | Insider | Sell | 75,873 | $90.00 | $6,828,570.00 | 18,041 | |
2/15/2018 | Gary A Lyons | Director | Sell | 5,000 | $84.67 | $423,350.00 | | |
2/12/2018 | Dimitri E Grigoriadis | Insider | Sell | 86,368 | $78.32 | $6,764,341.76 | 154,717 | |
2/9/2018 | Dimitri E Grigoriadis | Insider | Sell | 71,775 | $77.98 | $5,597,014.50 | 154,717 | |
2/6/2018 | Kevin Charles Gorman | CEO | Sell | 105,983 | $80.25 | $8,505,135.75 | 339,482 | |
2/5/2018 | Gary A Lyons | Director | Sell | 5,000 | $83.08 | $415,400.00 | 267,066 | |
2/5/2018 | Haig P Bozigian | Insider | Sell | 2,262 | $83.10 | $187,972.20 | 76,950 | |
1/24/2018 | William H Rastetter | Director | Sell | 9,500 | $90.00 | $855,000.00 | 34,250 | |
1/16/2018 | Haig P Bozigian | Insider | Sell | 1,625 | $79.12 | $128,570.00 | | |
1/16/2018 | Kevin Charles Gorman | CEO | Sell | 3,750 | $78.89 | $295,837.50 | | |
1/3/2018 | Darin Lippoldt | Insider | Sell | 1,979 | $79.36 | $157,053.44 | | |
12/28/2017 | Darin Lippoldt | Insider | Sell | 15,237 | $75.00 | $1,142,775.00 | | |
12/28/2017 | Darin Lippoldt | Insider | Sell | 15,237 | $75.00 | $1,142,775.00 | 28,394 | |
12/8/2017 | Darin Lippoldt | Insider | Sell | 2,955 | $75.00 | $221,625.00 | 16,112 | |
12/4/2017 | Darin Lippoldt | Insider | Sell | 6,279 | $75.04 | $471,176.16 | 19,436 | |
12/1/2017 | Gary A Lyons | Director | Sell | 10,000 | $72.92 | $729,200.00 | 272,066 | |
11/15/2017 | Darin Lippoldt | Insider | Sell | 9,900 | $73.05 | $723,195.00 | | |
11/8/2017 | Dimitri E Grigoriadis | Insider | Sell | 30,000 | $74.58 | $2,237,400.00 | 77,691 | |
11/2/2017 | Kyle Gano | Insider | Sell | 24,818 | $71.05 | $1,763,318.90 | 84,596 | |
10/2/2017 | Christopher Flint Obrien | Insider | Sell | 6,925 | $61.04 | $422,702.00 | 55,898 | |
9/6/2017 | Haig P Bozigian | Insider | Sell | 26,250 | $60.00 | $1,575,000.00 | 144,601 | |
9/5/2017 | Christopher Flint Obrien | Insider | Sell | 52,817 | $57.50 | $3,036,977.50 | 101,790 | |
8/9/2017 | Dimitri E Grigoriadis | Insider | Sell | 15,354 | $55.00 | $844,470.00 | 123,045 | |
8/4/2017 | Haig P Bozigian | Insider | Sell | 22,500 | $50.00 | $1,125,000.00 | 154,601 | |
7/27/2017 | Christopher Flint Obrien | Insider | Sell | 8,734 | $50.00 | $436,700.00 | 57,707 | |
5/23/2017 | Dimitri E Grigoriadis | Insider | Sell | 10,000 | $53.39 | $533,900.00 | 107,691 | |
5/19/2017 | Malcolm Lloyd-Smith | Insider | Sell | 9,960 | $53.63 | $534,154.80 | 17,997 | |
5/5/2017 | Corinne H Nevinny | Director | Sell | 5,000 | $53.98 | $269,900.00 | 34,603 | |
5/2/2017 | Dimitri E Grigoriadis | Insider | Sell | 10,000 | $55.00 | $550,000.00 | 117,691 | |
5/2/2017 | Kevin Charles Gorman | CEO | Sell | 21,739 | $53.23 | $1,157,166.97 | 354,346 | |
5/1/2017 | Kyle Gano | Insider | Sell | 15,000 | $54.00 | $810,000.00 | 88,246 | |
4/12/2017 | Haig P Bozigian | Insider | Sell | 13,065 | $50.42 | $658,737.30 | 129,805 | |
4/12/2017 | Kevin Charles Gorman | CEO | Sell | 19,596 | $50.42 | $988,030.32 | 332,913 | |
2/7/2017 | Malcolm Lloyd-Smith | Insider | Sell | 116 | $44.61 | $5,174.76 | | |
2/6/2017 | Dimitri E Grigoriadis | Insider | Sell | 727 | $43.13 | $31,355.51 | 115,756 | |
2/6/2017 | Kevin Charles Gorman | CEO | Sell | 3,010 | $43.18 | $129,971.80 | 250,542 | |
2/6/2017 | Timothy P Coughlin | CFO | Sell | 963 | $43.14 | $41,543.82 | 137,961 | |
2/3/2017 | Christopher Flint Obrien | Insider | Sell | 1,500 | $42.50 | $63,750.00 | 35,044 | |
2/3/2017 | Kevin Charles Gorman | CEO | Sell | 3,125 | $42.55 | $132,968.75 | 247,802 | |
2/1/2017 | William H Rastetter | Director | Sell | 10,750 | $42.28 | $454,510.00 | 25,000 | |
1/17/2017 | Haig P Bozigian | Insider | Sell | 1,625 | $40.63 | $66,023.75 | 114,704 | |
1/17/2017 | Kevin Charles Gorman | CEO | Sell | 3,750 | $40.65 | $152,437.50 | 244,677 | |
1/17/2017 | Timothy P Coughlin | CFO | Sell | 1,750 | $40.65 | $71,137.50 | 134,824 | |
1/10/2017 | Christopher Flint Obrien | Insider | Sell | 1,750 | $43.35 | $75,862.50 | 31,794 | |
1/10/2017 | Kevin Charles Gorman | CEO | Sell | 3,750 | $43.28 | $162,300.00 | 240,927 | |
11/15/2016 | Christopher Flint Obrien | Insider | Sell | 25,000 | $52.84 | $1,321,000.00 | 30,044 | |
9/1/2016 | Malcolm Lloyd-Smith | Insider | Sell | 9,000 | $50.00 | $450,000.00 | 9,000 | |
8/15/2016 | Christopher Flint Obrien | Insider | Sell | 12,500 | $48.73 | $609,125.00 | 55,044 | |
8/8/2016 | Corinne H Nevinny | Director | Sell | 5,000 | $48.54 | $242,700.00 | 25,555 | |
5/25/2016 | Richard F Pops | Director | Sell | 15,000 | $46.72 | $700,800.00 | 15,464 | |
5/16/2016 | Christopher Flint Obrien | Insider | Sell | 25,000 | $45.00 | $1,125,000.00 | 80,044 | |
4/11/2016 | Kyle Gano | Insider | Sell | 41,770 | $44.02 | $1,838,715.40 | 57,788 | |
4/6/2016 | Christopher Flint Obrien | Insider | Sell | 25,000 | $45.00 | $1,125,000.00 | 105,044 | |
2/3/2016 | Haig P Bozigian | Insider | Sell | 1,375 | $38.13 | $52,428.75 | 111,454 | |
2/3/2016 | Kevin Charles Gorman | CEO | Sell | 3,125 | $38.04 | $118,875.00 | 228,077 | |
2/3/2016 | Timothy P Coughlin | CFO | Sell | 1,500 | $38.06 | $57,090.00 | 131,374 | |
1/19/2016 | Haig P Bozigian | Insider | Sell | 1,625 | $46.77 | $76,001.25 | 110,079 | |
1/19/2016 | Kevin Charles Gorman | CEO | Sell | 3,750 | $46.70 | $175,125.00 | 224,952 | |
1/19/2016 | Timothy P Coughlin | CFO | Sell | 1,750 | $46.69 | $81,707.50 | 129,874 | |
1/11/2016 | Haig P Bozigian | Insider | Sell | 1,625 | $44.25 | $71,906.25 | 108,454 | |
1/11/2016 | Kevin Charles Gorman | CEO | Sell | 3,750 | $44.17 | $165,637.50 | 221,202 | |
1/11/2016 | Timothy P Coughlin | CFO | Sell | 1,750 | $44.25 | $77,437.50 | 128,124 | |
11/27/2015 | Dimitri E. Grigoriadis | insider | Sell | 10,000 | $57.50 | $575,000.00 | 105,308 | |
11/9/2015 | Darin Lippoldt | insider | Sell | 23,761 | $52.92 | $1,257,432.12 | | |
10/16/2015 | Haig P Bozigian | Insider | Sell | 25,000 | $47.78 | $1,194,500.00 | 106,829 | |
10/16/2015 | Kevin Charles Gorman | CEO | Sell | 33,500 | $47.77 | $1,600,295.00 | 217,452 | |
9/18/2015 | Gary A. Lyons | Director | Sell | 15,000 | $54.89 | $823,350.00 | 252,066 | |
7/20/2015 | Dimitri E Grigoriadis | Insider | Sell | 19,646 | $55.00 | $1,080,530.00 | | |
7/20/2015 | Timothy P Coughlin | CFO | Sell | 20,000 | $55.00 | $1,100,000.00 | | |
7/13/2015 | Dimitri E Grigoriadis | Insider | Sell | 10,000 | $50.00 | $500,000.00 | | |
7/13/2015 | Timothy P Coughlin | CFO | Sell | 20,000 | $50.00 | $1,000,000.00 | | |
6/23/2015 | W Thomas Mitchell | Director | Sell | 15,000 | $49.35 | $740,250.00 | | |
6/8/2015 | Christopher Flint Obrien | Insider | Sell | 10,000 | $45.00 | $450,000.00 | | |
6/8/2015 | Timothy P Coughlin | CFO | Sell | 60,000 | $45.08 | $2,704,800.00 | | |
3/24/2015 | Gary A Lyons | Director | Sell | 30,000 | $41.53 | $1,245,900.00 | | |
3/24/2015 | Kevin Charles Gorman | CEO | Sell | 40,000 | $41.53 | $1,661,200.00 | | |
2/10/2015 | Dimitri E Grigoriadis | Insider | Sell | 20,000 | $35.00 | $700,000.00 | | |
1/16/2015 | Christopher Flint Obrien | Insider | Sell | 1,750 | $30.79 | $53,882.50 | | |
1/16/2015 | Kevin Charles Gorman | CEO | Sell | 3,750 | $30.79 | $115,462.50 | | |
1/12/2015 | Kevin Charles Gorman | CEO | Sell | 3,750 | $28.43 | $106,612.50 | | |
1/12/2015 | Kyle Gano | Insider | Sell | 1,250 | $28.41 | $35,512.50 | | |
1/12/2015 | Timothy P Coughlin | CFO | Sell | 1,750 | $28.37 | $49,647.50 | | |
1/8/2015 | Dimitri E Grigoriadis | Insider | Sell | 30,000 | $27.35 | $820,500.00 | | |
1/8/2015 | Kevin Charles Gorman | CEO | Sell | 25,000 | $27.39 | $684,750.00 | | |
1/8/2015 | Timothy P Coughlin | CFO | Sell | 10,000 | $27.25 | $272,500.00 | | |
1/5/2015 | Dimitri E Grigoriadis | Insider | Sell | 2,500 | $22.76 | $56,900.00 | | |
1/2/2015 | W Thomas Mitchell | Director | Sell | 8,000 | $22.79 | $182,320.00 | | |
12/19/2014 | Christopher Flint Obrien | Insider | Sell | 20,000 | $24.02 | $480,400.00 | | |
12/19/2014 | Kevin Charles Gorman | CEO | Sell | 70,000 | $23.41 | $1,638,700.00 | | |
12/19/2014 | Timothy P Coughlin | CFO | Sell | 30,000 | $23.46 | $703,800.00 | | |
12/17/2014 | Kyle Gano | Insider | Sell | 4,957 | $22.50 | $111,532.50 | | |
12/15/2014 | Dimitri E Grigoriadis | Insider | Sell | 12,794 | $22.35 | $285,945.90 | | |
12/12/2014 | Kyle Gano | Insider | Sell | 4,043 | $22.50 | $90,967.50 | | |
12/11/2014 | Christopher Flint Obrien | Insider | Sell | 40,000 | $21.82 | $872,800.00 | | |
12/10/2014 | Timothy P Coughlin | CFO | Sell | 20,000 | $21.48 | $429,600.00 | | |
12/10/2014 | W Thomas Mitchell | Director | Sell | 7,000 | $21.90 | $153,300.00 | | |
11/28/2014 | Timothy P Coughlin | CFO | Sell | 10,000 | $20.14 | $201,400.00 | | |
11/24/2014 | Christopher Flint Obrien | Insider | Sell | 5,463 | $19.53 | $106,692.39 | | |
10/31/2014 | Timothy P Coughlin | CFO | Sell | 10,000 | $19.00 | $190,000.00 | | |
10/30/2014 | Timothy P Coughlin | CFO | Sell | 20,000 | $18.31 | $366,200.00 | | |
10/1/2014 | W Thomas Mitchell | Director | Sell | 1,275 | $15.50 | $19,762.50 | | |
9/15/2014 | Gary A Lyons | Director | Sell | 20,000 | $15.66 | $313,200.00 | | |
1/17/2014 | Dimitri Grigoriadis | Insider | Sell | 25,000 | $20.00 | $500,000.00 | 77,058 | |
1/10/2014 | Christopher Flint Obrien | Insider | Sell | 6,750 | $18.88 | $127,440.00 | 96,544 | |
1/10/2014 | Kevin Charles Gorman | CEO | Sell | 3,750 | $18.57 | $69,637.50 | 180,952 | |
1/10/2014 | Timothy Coughlin | CFO | Sell | 1,750 | $18.56 | $32,480.00 | 97,874 | |
1/7/2014 | Dimitri Grigoriadis | Insider | Sell | 25,000 | $17.50 | $437,500.00 | 75,433 | |
1/7/2014 | Kevin Charles Gorman | CEO | Sell | 108,000 | $16.76 | $1,810,080.00 | 177,202 | |
1/7/2014 | Timothy Coughlin | CFO | Sell | 70,000 | $16.75 | $1,172,500.00 | 96,124 | |
9/4/2013 | Kyle Gano | Insider | Sell | 2,400 | $15.61 | $37,464.00 | 22,488 | |
9/3/2013 | Christopher Flint Obrien | Insider | Sell | 5,000 | $16.00 | $80,000.00 | 94,794 | |
8/21/2013 | Haig Bozigian | Insider | Sell | 13,999 | $15.04 | $210,544.96 | 76,954 | |
8/21/2013 | Timothy Coughlin | CFO | Sell | 19,035 | $15.05 | $286,476.75 | 96,124 | |
8/6/2013 | W Thomas Mitchell | Director | Sell | 1,531 | $14.70 | $22,505.70 | 1,000 | |
8/5/2013 | Haig Bozigian | Insider | Sell | 11,001 | $15.00 | $165,015.00 | 76,954 | |
8/5/2013 | Timothy Coughlin | CFO | Sell | 10,965 | $14.99 | $164,365.35 | 96,124 | |
7/12/2013 | Christopher Flint Obrien | Insider | Sell | 5,000 | $14.50 | $72,500.00 | | |
6/28/2013 | Christopher Flint Obrien | Insider | Sell | 11,357 | $13.33 | $151,388.81 | | |
6/27/2013 | Haig P Bozigian | Insider | Sell | 8,000 | $13.00 | $104,000.00 | | |
6/21/2013 | Dimitri E Grigoriadis | Insider | Sell | 46,837 | $12.51 | $585,930.87 | | |
(Data available from 1/1/2013 forward)
Neurocrine Biosciences (NASDAQ NBIX) News Headlines
Source: |
|
Date | Headline |
---|
 | Neurocrine Biosciences to Present New Data from INGREZZA® at the 2018 American Academy of Neurology Annual ... www.prnewswire.com - April 19 at 5:15 PM |
 | SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Neurocrine Biosciences, Inc. for Potential ... www.prnewswire.com - April 19 at 5:15 PM |
 | SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Neurocrine Biosciences, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors finance.yahoo.com - April 19 at 8:42 AM |
 | Neurocrine Biosciences to Present New Data from INGREZZA® at the 2018 American Academy of Neurology Annual Meeting finance.yahoo.com - April 18 at 5:22 PM |
 | Brokerages Anticipate Neurocrine Biosciences (NBIX) Will Announce Quarterly Sales of $65.97 Million www.americanbankingnews.com - April 17 at 2:33 AM |
 | Neurocrine Biosciences (NBIX) Expected to Announce Earnings of -$0.32 Per Share www.americanbankingnews.com - April 15 at 7:17 PM |
 | Oppenheimer Comments on Neurocrine Biosciences' Q2 2018 Earnings (NBIX) www.americanbankingnews.com - April 13 at 8:51 AM |
 | Ingrezza: Boosting Neurocrine’s Top Line finance.yahoo.com - April 12 at 5:10 PM |
 | Neurocrine Biosciences (NBIX) Receives "Outperform" Rating from Cowen www.americanbankingnews.com - April 11 at 11:23 PM |
 | Neurocrine Biosciences (NBIX) Upgraded by BidaskClub to "Buy" www.americanbankingnews.com - April 11 at 8:59 PM |
 | Neurocrine Biosciences (NBIX) Given a $110.00 Price Target by Oppenheimer Analysts www.americanbankingnews.com - April 10 at 3:29 PM |
 | AbbVie : PDUFA Target Date Of Q3 For Elagolix In Endometriosis-Associated Pain www.nasdaq.com - April 10 at 9:01 AM |
 | A Sixth Sense For Biotech Has Made Joe Edelman A Hedge Fund Star finance.yahoo.com - April 10 at 9:01 AM |
 | AbbVie and Neurocrine Biosciences Announce PDUFA Target Date of Q3 2018 for Elagolix in Endometriosis-Associated Pain finance.yahoo.com - April 10 at 9:01 AM |
 | FDA needs more time to review AbbVie, Neurocrine's uterine pain drug finance.yahoo.com - April 10 at 9:01 AM |
 | FDA extends review for AbbVie, Neurocrine's uterine pain drug finance.yahoo.com - April 10 at 9:01 AM |
 | Neurocrine Biosciences (NBIX) Given "Buy" Rating at Piper Jaffray www.americanbankingnews.com - April 5 at 12:39 PM |
 | Neurocrine Biosciences (NBIX) Downgraded by BidaskClub www.americanbankingnews.com - April 4 at 9:30 AM |
 | Neurocrine Biosciences (NBIX) Rating Increased to Buy at ValuEngine www.americanbankingnews.com - April 3 at 11:38 AM |
 | Neurocrine Biosciences (NBIX) Stock Rating Reaffirmed by Citigroup www.americanbankingnews.com - April 2 at 12:30 AM |
 | Deutsche Bank Reiterates "Buy" Rating for Neurocrine Biosciences (NBIX) www.americanbankingnews.com - April 1 at 11:24 PM |
 | Zacks: Brokerages Anticipate Neurocrine Biosciences, Inc. (NBIX) Will Post Quarterly Sales of $66.03 Million www.americanbankingnews.com - March 31 at 1:56 AM |
 | Neurocrine Biosciences, Inc. (NBIX) Given Consensus Recommendation of "Buy" by Brokerages www.americanbankingnews.com - March 31 at 1:36 AM |
 | Neurocrine Biosciences (NBIX) Upgraded by BidaskClub to Buy www.americanbankingnews.com - March 30 at 5:40 PM |
 | Analysts Expect Neurocrine Biosciences, Inc. (NBIX) Will Post Earnings of -$0.32 Per Share www.americanbankingnews.com - March 29 at 11:26 PM |
 | Neurocrine Biosciences (NBIX) Given a $95.00 Price Target at Oppenheimer www.americanbankingnews.com - March 28 at 3:48 PM |
 | Needham & Company LLC Raises Neurocrine Biosciences (NBIX) Price Target to $95.00 www.americanbankingnews.com - March 28 at 2:42 PM |
 | Neurocrine Biosciences (NBIX) Downgraded by BidaskClub to "Buy" www.americanbankingnews.com - March 24 at 1:17 PM |
 | Neurocrine Biosciences (NBIX) Receives "Buy" Rating from Oppenheimer www.americanbankingnews.com - March 22 at 10:54 PM |
 | Loss-Making Neurocrine Biosciences Inc (NASDAQ:NBIX) Expected To Breakeven finance.yahoo.com - March 20 at 8:58 AM |
 | Neurocrine Biosciences, Inc. (NBIX) Expected to Post Q4 2018 Earnings of $0.43 Per Share www.americanbankingnews.com - March 16 at 12:36 PM |
 | FY2019 EPS Estimates for Neurocrine Biosciences, Inc. Lowered by Analyst (NBIX) www.americanbankingnews.com - March 15 at 12:42 PM |
 | Neurocrine Biosciences (NBIX) Rating Reiterated by Piper Jaffray Companies www.americanbankingnews.com - March 15 at 12:58 AM |
 | Is This AbbVie's Next Blockbuster Drug? www.msn.com - March 14 at 6:34 PM |
 | AbbVie Announces Positive Topline Results from Second Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids www.prnewswire.com - March 13 at 8:55 AM |
 | Zacks: Analysts Expect Neurocrine Biosciences, Inc. (NBIX) to Announce -$0.32 Earnings Per Share www.americanbankingnews.com - March 12 at 9:13 PM |
 | Insider Selling: Neurocrine Biosciences, Inc. (NBIX) Insider Sells 75,873 Shares of Stock www.americanbankingnews.com - March 7 at 6:48 PM |
 | Neurocrine Biosciences to Present at Upcoming Healthcare Conferences finance.yahoo.com - March 7 at 6:01 PM |
 | Allianz Asset Management GmbH Boosts Stake in Neurocrine Biosciences, Inc. (NBIX) www.americanbankingnews.com - March 6 at 4:16 AM |
 | Neurocrine Biosciences, Inc. (NBIX) Receives Consensus Recommendation of "Buy" from Analysts www.americanbankingnews.com - March 6 at 1:36 AM |
 | Neurocrine Biosciences, Inc. (NBIX) Shares Sold by Sectoral Asset Management Inc www.americanbankingnews.com - March 5 at 3:35 PM |
 | 20,000 Shares in Neurocrine Biosciences, Inc. (NBIX) Purchased by Eaton Vance Management www.americanbankingnews.com - March 5 at 10:08 AM |
 | Schroder Investment Management Group Lowers Position in Neurocrine Biosciences, Inc. (NBIX) www.americanbankingnews.com - March 5 at 9:02 AM |
 | Quotidian Technical Highlights on Selected Generic Drugs Stocks -- Mallinckrodt, Momenta Pharma, Mylan, and Neurocrine Biosciences www.bizjournals.com - March 5 at 8:45 AM |
 | Emory University Sells 5,537 Shares of Neurocrine Biosciences, Inc. (NBIX) www.americanbankingnews.com - March 4 at 2:59 PM |
 | Neurocrine Biosciences, Inc. (NBIX) Holdings Decreased by Rhumbline Advisers www.americanbankingnews.com - March 4 at 10:30 AM |
 | UBS Asset Management Americas Inc. Sells 54,520 Shares of Neurocrine Biosciences, Inc. (NBIX) www.americanbankingnews.com - February 28 at 5:37 PM |
 | Bank of New York Mellon Corp Has $115.27 Million Holdings in Neurocrine Biosciences, Inc. (NBIX) www.americanbankingnews.com - February 27 at 4:42 AM |
 | OppenheimerFunds Inc. Acquires 226,127 Shares of Neurocrine Biosciences, Inc. (NBIX) www.americanbankingnews.com - February 26 at 1:48 PM |
 | FY2021 EPS Estimates for Neurocrine Biosciences, Inc. (NBIX) Raised by Analyst www.americanbankingnews.com - February 26 at 10:08 AM |
Neurocrine Biosciences (NASDAQ:NBIX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Neurocrine Biosciences (NASDAQ:NBIX) Income Statement, Balance Sheet and Cash Flow Statement
Neurocrine Biosciences (NASDAQ NBIX) Stock Chart for Monday, April, 23, 2018
Loading chart…